Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers

Documenti analoghi

• Steady‐State Pharmacokinetic Properties of TNX‐102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open‐Label Trial
  di: Gregory M. Sullivan, et al.
  Pubblicazione: (2026)
• Pooled Efficacy From Two Phase 3 Pivotal Trials (RELIEF AND RESILIENT) of TNX‐102 SL, Cyclobenzaprine HCl Sublingual Tablets, in Participants with Fibromyalgia
  di: Errol Gould, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Bioequivalence of Fixed‐Dose Combination of Simvastatin and Ezetimibe Tablets: A Randomized, Crossover, Open‐Label Study in Healthy Volunteers
  di: Chuei Wuei Leong, et al.
  Pubblicazione: (2024)
• Bioequivalence and Pharmacokinetic Evaluation of Regorafenib Tablets in Healthy Chinese Volunteers
  di: Zhaoyu Wang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open‐Label, Crossover Study in Fasting Healthy Volunteers
  di: Kar Ming Yee, et al.
  Pubblicazione: (2025)